One-time gene therapy could end lifelong transfusions for rare blood disease

Thanks to in-utero blood transfusion technology, what was once a fatal diagnosis in the womb can now result in live births. However, this medical advancement created a new challenge: a growing population of children born with that diagnosis—the severe, inherited blood disorder alpha thalassemia—which requires lifelong specialized care.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup